Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia

Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with high mortality that urgently requires new treatments. ROCK1 plays an essential role in regulating growth and survival in AML cells. In this study, we evaluated GSK269962A, a selective ROCK1 inhibitor, in preclinical models of...

Full description

Bibliographic Details
Main Authors: Ting Pan, Sijia Wang, Hao Feng, Jiawen Xu, Miao Zhang, Yao Yao, Kailin Xu, Mingshan Niu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
acute myeloid leukemia
targeted therapy
ROCK1
GSK269962A
ERK
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1064470/full

Similar Items

Similar Items